BioCryst Pharmaceuticals | BCRX - Los Gastos De Explotación





Los Gastos De Explotación Cambio Fecha
Alnylam Pharmaceuticals USD 898.54M 66.78M 2026-03
BioCryst Pharmaceuticals USD 146.17M 534.06M 2025-12
Chugai Pharma JPY 162.98B 14.31B 2026-03
Daiichi Sankyo JPY 468.57B 15.34B 2025-12
DBV Technologies USD 37.05M 4.06M 2025-09
Enanta Pharmaceuticals USD 126.59M 346.51M 2025-12
Gilead Sciences USD 4.96B 707M 2025-12
GlaxoSmithKline GBP 5.34B 1.85B 2026-03
Glaxosmithkline GBP 9.17B 1.4B 2025-12
Incyte USD 5.62B 4.5B 2026-03
Ionis Pharmaceuticals USD 364M 54M 2026-03
Karyopharm Therapeutics USD 51.92M 9.9M 2025-12
Neurocrine Biosciences USD 577.6M 22M 2025-12
Novavax USD 126.2M 23.62M 2025-12
PTC Therapeutics USD 246.3M 38.78M 2025-12
Regeneron Pharmaceuticals USD 31.42B 28.44B 2026-03
Roche Holding CHF 21.01B 10.84B 2025-12
Sarepta Therapeutics USD 853.02M 390.78M 2025-12
Ultragenyx Pharmaceutical USD 321M 9.82M 2025-12
Vertex Pharmaceuticals USD 1.85B 78.6M 2026-03